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ABSTRACT 
 
Introduction: Antimicrobial resistance threatens to undermine treatment for severe infection; new 
therapeutic strategies are urgently needed. Pre-clinical work shows that augmented passive 
immunotherapy with P4 peptide increases phagocytic activity and shows promise as a novel 
therapeutic strategy. Our aim was to determine ex vivo P4 activity in a target population of patients 
admitted to critical care with severe infection. 
Methods: We prospectively recruited UK critical care unit patients with severe sepsis and observed 
clinical course (≥3 months post discharge). Blood samples were taken in early (≤ 48hrs post-
diagnosis, n=54), latent (seven days post-diagnosis, n=39) and convalescent (3-6 months post-
diagnosis, n=18) phases of disease. The primary outcome measure was killing of opsonised 
S.pneumoniae by neutrophils with and without P4 peptide stimulation. We also used a flow 
cytometric whole blood phagocytosis assay to determine phagocyte association and oxidation of 
intraphagosomal reporter beads.  
Results: P4 peptide increased neutrophil killing of opsonised pneumococci by 8.6% (C.I. 6.35 – 
10.76, p<0.001) in all phases of sepsis, independent of infection source and microbiological status. 
This represented a 54.9% increase in bacterial killing compared to unstimulated neutrophils 
(15.6%) in early phase samples. Similarly, P4 peptide treatment significantly increased neutrophil 
and monocyte intraphagosomal reporter bead association and oxidation, independent of infection 
source. 
Conclusions: We have extended pre-clinical work to demonstrate that P4 peptide significantly 
increases phagocytosis and bacterial killing in samples from a target patient population with severe 
sepsis. This study supports the rationale for augmented passive immunotherapy as a therapeutic 
strategy in severe sepsis. 
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INTRODUCTION 
 
Severe sepsis is a worldwide public health concern despite recent advances and standardisation in 
treatment (1–3). The current evidence base for effective therapies is limited to antibiotics, source 
control and organ support (4). In this context, antimicrobial resistance is of immediate concern and 
has been described as ‘a threat to national security’ by prominent health leaders (5). Augmented 
passive immunotherapy using a peptide fragment of pneumococcal surface adhesin A (PsaA) to 
stimulate phagocytic cells is one alternative therapeutic strategy that shows promise (6). 
 
P4 peptide is a 28 amino acid fragment of PsaA, a protein expressed on the surface of Streptococcus 
pneumoniae. Initially investigated as a vaccine candidate, it was discovered that P4 peptide 
stimulation promotes increased bacterial (including Streptococcus pneumoniae, Streptococcus 
pyogenes, Neisseria meningitidis and Staphylococcus aureus) binding by phagocytic cells (7,8). 
Following this, multiple in vivo investigations have shown that the administration of P4 peptide in 
combination with immunoglobulin rescues moribund mice from death in streptococcal and 
staphylococcal infection models (8–14). Further, healthy human alveolar macrophages demonstrate 
improved bacterial killing when exposed to P4 peptide ex vivo (15). However, patients with severe 
infection develop marked immune dysregulation, negatively impacting on innate and adaptive 
immune function (16). Thus, it is unclear if the effects of P4 peptide observed in vitro and in vivo 
will also apply to our target population – patients with severe sepsis. 
 
The aim of our study was to test the effect of P4 peptide on phagocytic cells ex vivo from patients 
admitted to critical care with severe sepsis. Determination of P4 peptide activity in this target 
population will support the translation of this promising therapeutic strategy to future clinical trials 
and clinical utility.  
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MATERIALS AND METHODS 
 
Clinical 
We recruited patients admitted to critical care with severe sepsis according to ACCP-SCCM 2001 
criteria (17) at Aintree University Hospital and Royal Liverpool University Hospital, UK (February 
2014  - June 2015). Patient inclusion criteria: age ≥18, recruitment ≤48hours diagnosis, severe 
sepsis from respiratory, abdominal or urogenital source (predominant causes (18)). Patient 
exclusion criteria were: immunocompromising condition or therapy, pregnancy, responsible 
clinician deemed inappropriate, co-enrolment in another study that could have influenced results or 
failed to obtain consent. Blood samples were taken at day 0, 7 and 3-6 months to determine 
phagocyte function in the early, latent and convalescent phases of infection. Previous work has 
demonstrated suppression of neutrophil response in the latent phase of infection (19). Our aim was 
to capture this phase to determine peptide activity and follow with convalescent samples after 
patients had been discharged home. Healthy volunteers were recruited and sampled at matched 
intervals (Clinical Research Facility, Royal Liverpool University Hospital) to determine assay 
stability and validate components. Healthy volunteers inclusion were: no current illness, aged >18 
and able to travel to the research facility. Healthy volunteer exclusion criteria were the same as for 
patients. The UK NHS Research Ethics Committee granted approval for this project (13/WA/0353). 
Written consent was obtained for all participants. A CONSORT diagram that details patient 
screening and inclusion is provided in Figure S1 - Supplemental Digital Content.  
 
Laboratory 
P4 peptide and M12-1 peptide were synthesized and purified by Centers for Disease Control, 
Georgia, USA and reconstituted in diethylpyrocarbonate (DEPC) water. The primary outcome 
measure was neutrophil bacterial killing determined by a standardised opsonophagocytosis assay 
(with minor modifications (20)).  Briefly, neutrophils were isolated from heparinized blood by 
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density centrifugation and incubated (45 minutes, 37oC, shaking 300 RPM) with live pneumococci 
(capsulated serotype 2, D39 strain), human intravenous immunoglobulin (Gammunex, Grifols, 
Inc.), baby rabbit complement (Mast Group, UK) and P4 peptide (1mg/ml) or control (M12-1 
peptide 1mg/ml and DEPC vehicle). The dose of P4 peptide in this assay was based on previously 
published work (8). The multiplicity of infection was 100:1 (neutrophil: bacteria). Plates were 
cooled (4oC) to arrest phagocytic activity and the mixture incubated for 18-24 hours (blood agar, 
37oC, 5% CO2) before colony forming unit enumeration. All samples were performed in triplicate. 
Neutrophil bacterial killing index is defined as: 1 – (experimental well divided by non-PMN control 
well). Experimental components were: neutrophils (PMN), opsonised bacteria and complement 
with P4 peptide, M12-1 peptide or vehicle control. Non-PMN components were: opsonised 
bacteria, complement. See Supplemental Digital Content for full details of experimental methods. 
 
Our whole blood phagocytosis assay built on previous work (21). After venepuncture, citrated 
blood (4.5ml, BD) was placed on an automated mixer at room temperature. The intraphagosomal 
reporter beads constitute IgG coated silica beads with calibrator (Pacific Blue, Invitrogen) and 
reporter (OxyBurst Green, Invitrogen) fluorochromes. Beads were reconstituted (30 x106/ml) in 
Roswell Park Memorial Institute media (Invitrogen, US) and mixed with experimental solution 
(4mg/ml P4 peptide or plain DEPC): 5:1 ratio. This dose was based on a P4 peptide titration 
experiment (supplemental digital content). Subsequently, paired 120μl aliquots (0, 10, 20, 30, 45 
and 60 minutes) were incubated with whole blood (100μl) at 37oC in the dark. Multiple 
fluorescence minus one controls were used to set negative and positive boundaries for analysis 
(Figure S2, Supplemental Digital Content). After allotted incubation time, samples were rapidly 
cooled (4oC) to arrest biological activity, red cells treated with lysis buffer (Biolegend, US) and 
samples washed before flow cytometric acquisition. In preliminary work, cell surface markers were 
used to define monocyte populations (CD14, BD Pharmingen) and estimate neutrophil function 
(CD66b, Stemcell). Compensation beads (BD Biosciences) were used to create compensation 
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matrices. Cell populations of interest were identified by sequential cell gating strategies. Samples 
were acquired using a BD LSRII Flow Cytometer equipped with three lasers (405, 488 and 633nm, 
Becton Dickinson) using FacsDiva (version 6.1, BD Biosciences) and FlowJo (version 10.7, Tree 
Star) flow cytometry software. 
 
Statistics 
Data were examined for normality before appropriate tests applied. All patient samples were 
analysed pairwise (P4 peptide vs. vehicle or peptide control). Mixed model regression analyses 
were used to allow the hierarchical nature of patient sampling (one patient repeatedly sampled three 
times). Three mixed models were employed for the main analyses: Model one had neutrophil 
bacterial killing (%) as the dependent variable, phase of infection (early, latent, convalescent) and 
group (P4 peptide, control) as fixed effects and patient as random effect. Model two had neutrophil-
intraphagosomal reporter bead association as dependent variables, phase of infection (early, latent, 
convalescent), group (P4 peptide, control), time (0, 10, 20, 30, 45, 60 min), and interaction between 
group and time as fixed effects, and patient as random effect. Model three had intraphagosomal 
reporter bead oxidation ratio as the dependent variable with fixed and random effects as per model 
2. The differences between P4 peptide and control in mean of those outcomes at different time 
points together 95% CI were derived from the mixed models. Mixed model regression assumes that 
missing values are at random.  Mann-Whitney U Test was used when normality assumption was 
violated. All data was analysed using STATA 13.1 (Statacorp). 
 
RESULTS 
 
Patient recruitment – clinical details and microbiology 
Fifty-four patients were recruited to this study; 30 (55.6%) were men and median age was 63.5 
(IQR 53-75). Fifty-two patients were of white ethnic origin, one Asian and one black. There were 
17 smokers and median body mass index was 27.3 (IQR 24.0-31.3). Pre-morbid status was 
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quantified using Charlson-Index score ((22) median 2, IQR 1-3). The most common pre-morbid 
conditions were: hypertension (14), type 2 diabetes mellitus (11), chronic obstructive pulmonary 
disease (10) and ischaemic heart disease (7). The median acute physiology and chronic health 
evaluation two score (APACHE II) was 19 (IQR: 14-23). The median sequential organ failure 
assessment (SOFA) score at critical care admission was 8 (IQR: 5-10). Table 1 describes illness 
severity parameters at each phase of infection. No patients were readmitted to critical care between 
latent and convalescent phases. Table 2 describes clinical outcomes in this patient cohort. Thirty-
eight patients had positive microbiological samples (17 positive blood cultures, 9 bronchoalveolar 
lavage, 9 tracheal aspirate, 12 sputum, 9 urine and 18 abdominal swabs). The most common 
organisms identified by blood culture were: Escherichia coli (9), Streptococcus pneumoniae (3) and 
Klebsiella species (2). The source of infection was respiratory in 26 patients, abdominal in 21 and 
urogenital in 7. In common with previous work (23), microbiological yield was lower for 
respiratory infection (16/26) compared to abdominal (16/21) and urogenital (6/7), p=0.043 
(Kruskall-Wallis). In our cohort, 11/16 samples from patients with respiratory infection grew gram-
positive organisms.  
 
Eleven healthy volunteers were recruited to this study (6 male) with a median age of 21 (IQR 21 – 
27). All of the healthy volunteers were of white ethnic origin, there were no smokers and median 
body mass index was 24.5 (IQR 22.1 – 28.3). The volunteers had no pre-morbid conditions (median 
Charlson Index score 0, IQR 0 – 0). Three samples of venous blood were taken at intervals matched 
to that of the critical care patients (i.e. time 0, 1 week later and 3-6 months later).  
 
Opsonophagocytosis assay: P4 peptide stimulated increased bacterial killing. 
Neutrophil bacterial killing was 54.9% higher in P4 stimulated cells compared to paired controls 
(24.13% vs. 15.57%, p<0.001). The was no interaction between P4 peptide effect and phase of 
infection, such that stimulated neutrophils demonstrated increased bacterial killing (8.55%, 
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p<0.001) in early, latent and convalescent infection (Figure 1). Raw data and details of the mixed 
model regression analysis are provided in the supplemental digital content (opsonophagocytosis 
assay analysis). There was no difference between DEPC and M12-1 peptide control 16.65% vs. 
14.78%, p=0.366 (Figure S3, Supplemental Digital Content).  In the mixed-model regression 
analysis, the source of infection (respiratory 26, abdominal 21, urogenital 7) was not associated 
with P4 peptide activity. In addition, smoking status did not impact upon phagocytic function in this 
cohort. However, phase of infection was independently associated with baseline bacterial killing 
and was significantly increased in the latent and convalescent compared to early phase samples. We 
found no significant difference in mean of neutrophil bacterial killing between patients with 
positive microbiology compared to negative in early phase samples either in control (14.15% vs. 
17.89%, p=0.208) or P4 peptide stimulated experiments (23.49% vs. 26.69%, p=0.273), unpaired t-
tests. In an exploratory analysis, clinical laboratory white cell, neutrophil and platelet counts were 
not associated with baseline neutrophil bacterial killing or response to P4 peptide in early phase 
samples (Tables S1 and S2 supplemental digital content). This study was not adequately powered to 
formally investigate the effect of P4 on samples from healthy volunteers, but the results were 
consistent with the patient samples: P4 peptide lead to significantly increased mean of neutrophil 
bacterial killing at blood sample one (day 0: 37.7% vs. 27.9%, p<0.001 C.I. 7.0 – 12.6), blood 
sample two (day 7: 34.4% vs. 24.5%, p<0.001 C.I. 7.0 – 12.6) and blood sample three (month 3: 
34.0% vs. 24.2% p<0.001 C.I. 7.0 – 12.6), mixed model regression analysis. Thus, baseline (vehicle 
control) neutrophil activity was initially lower in patient samples before recovery toward healthy 
volunteer levels (early 15.5%, latent 20.1% and convalescent 23.2% - Figure 1). 
 
Whole blood phagocytosis assay: P4 peptide stimulates increased reporter bead association 
and oxidation 
P4 peptide stimulation significantly increased intraphagosomal bead association (Figure 2A) and 
intraphagosomal bead oxidation (Figure 2B) compared to paired vehicle control. Raw data and 
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details of the mixed model regression analysis are provided in the supplemental digital content 
(whole blood phagocytosis assay: neutrophil-bead association analysis and whole blood 
phagocytosis assay: neutrophil intraphagosomal reporter bead oxidation analysis). A significant 
interaction was found between duration of incubation and P4 peptide stimulation in both reporter 
bead association and oxidation analyses. In these mixed-model regression analysis, source of 
infection (respiratory 21, abdominal 17 and urogenital 6) was not independently associated with P4 
peptide activity but baseline (vehicle control) bead association and oxidation were significantly 
decreased in the latent and convalescent phases of infection. There was no significant difference in 
bead association or oxidation (area under the curve calculation) between patients with positive 
microbiology compared to negative in early phase samples exposed to vehicle control and P4 
peptide, using unpaired t-tests. Additionally, in a non-powered cohort of healthy volunteers, 
treatment with P4 peptide stimulated increased neutrophil-bead association compared to vehicle 
control (Figure S4, Supplemental Digital Content).  
 
Neutrophil CD66b expression 
Neutrophils with increased expression of CD66b are associated with an up-regulated respiratory 
burst in samples isolated from patients with severe sepsis (24). Baseline CD66b was higher in early 
phase compared to latent phase samples (Figure 3A) and this was associated with greater 
neutrophil-bead association (Figure 3B). There was no difference in expression between samples 
exposed to P4 peptide or vehicle control. 
 
Monocyte activity 
Monocytes were identified by cell surface expression of CD14 in 51/94 of blood samples taken 
from patients for the whole blood phagocytosis assay. Seven samples identified less than 750 
monocytes and were excluded from the analysis. P4 peptide stimulated monocytes had significantly 
increased intraphagosomal reporter bead association in early, latent and convalescent phases of 
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sepsis by 8.3% (C.I. 3.4 – 13%, p=0.001). Monocyte oxidation ratio was significantly increased in 
samples exposed to P4 peptide compared to vehicle control (1.39 vs. 1.05, C.I. 0.23 – 0.44, 
p<0.001). Raw data and details of the mixed model regression analysis are provided in the 
supplemental digital content (whole blood phagocytosis assay: monocyte-bead association analysis 
and whole blood phagocytosis assay: monocyte intraphagosomal reporter bead oxidation analysis). 
 
DISCUSSION 
 
We found that augmented passive immunotherapy ex vivo using P4 peptide stimulation significantly 
increased neutrophil bacterial killing in samples from patients with severe sepsis. This effect was 
independent of the source, microbiological status and phase of infection. These data are 
corroborated by the whole blood phagocytosis assay that demonstrated P4 mediated increase in 
intraphagosomal reporter bead association and oxidation. This study demonstrates evidence that 
augmented passive immunotherapy has promise as a potential therapeutic strategy for patients with 
severe infection.  
 
We recruited patients admitted to critical care with severe infection with a wide range of co-
morbidities, infecting pathogens, severity of illness and age. Therefore, our cohort represents a 
broad spectrum of critically ill patients who could potentially benefit from treatment with 
augmented passive immunotherapy. Importantly, we have demonstrated a persistent response to P4 
peptide in the latent phase of sepsis. Down-regulation of the immune system leaves patients prone 
to secondary hospital-acquired infection so this strategy of phagocyte stimulation may also benefit 
patients during later stages of disease (16). 
 
Historically, adjuvant immunotherapies have failed to improve outcomes for patients with 
community-acquired pneumonia and sepsis (6). However, there is increasing focus on 
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immunostimulatory therapies (25) for infection with recent work exploring the efficacy of IL-7 and 
PD-L1 (26) in modulating T-cell responses and GM-CSF (NCT01653665) and interferon-gamma 
(NCT01649921) in modulating innate immune responses. Our study supports the addition of 
augmented passive immunotherapy with P4 peptide to the list of potential immunostimulatory 
adjuvant therapies for severe infection. Treatment with augmented passive immunotherapy has 
previously been shown to rescue moribund septic mice either alone or in combination with 
antibiotics (9).  The risk of immune hyperstimulation and organ injury is of concern for 
immunostimulatory therapies (27). However, P4 peptide does not stimulate inflammatory cytokine 
release ex vivo (15) and activated neutrophils can be retained and ‘de-primed’ within the lungs (28). 
This mechanism of de-priming is reduced for patients with adult respiratory distress syndrome 
(ARDS) therefore the potential detrimental effects of P4 peptide in this specific context require 
further investigation. 
 
We used two robust methods to determine phagocytic activity.  First, the opsonophagocytosis 
killing assay is an established and standardised method (29), widely used to compare phagocytic 
function in vaccine efficacy testing (30) and applied in previous work with P4 peptide (7,8,12,15). 
As previously described (15), P4 mediated effects on phagocyte bacterial uptake depend on 
pathogen opsonisation. Our study investigated Strep. pneumoniae but previous a in vitro study has 
demonstrated that P4 peptide can increase phagocytic uptake of opsonised gram-positive and gram-
negative bacteria (8). We used pooled human IVIG as a standardised opsonin in our 
opsonophagocytosis killing assay.  Future clinical investigation could employ P4 peptide 
administered with human IVIG as an empirical opsonin against a range of bacteria (6). We used a 
secondary whole blood phagocytosis assay to compliment the opsonophagocytosis assay using 
silica beads opsonised with human immunoglobulin. The aims of this assay were to reduce sample 
pre-processing and attempt to maintain the influence of inflammatory mediators. We chose a kinetic 
assay (multiple incubation intervals) to determine how P4 peptide influenced both the magnitude 
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and timing of oxidative burst. Incubation intervals were based on previous work (21,31) that 
demonstrates  maximal oxidative burst at 30 minutes of exposure to the phagosome. 
 
Whilst both the opsonophagocytosis and whole blood phagocytosis assays demonstrated that P4 
peptide stimulation augmented neutrophil activity, there were differences in baseline (non-
stimulated) neutrophil activity at different phases of infection. Down-regulation of the immune 
system and impaired neutrophil activity has been observed after an initial hyper-immune response 
to infection – characterised by the ‘compensatory anti-inflammatory response syndrome’ model of 
immune activity (32). Our whole blood phagocytosis assay data demonstrated this effect but the 
opsonophagocytosis assay did not (Figures 1 & 2). We hypothesised that density isolation and 
purification of neutrophils in the opsonophagocytosis assay would preferentially select mature 
neutrophils (33) and discarded lower density, less mature cells. We therefore used neutrophil 
CD66b expression, a marker associated with integrin-mediated adhesion and generation of reactive 
oxygen species (24), as a surrogate for neutrophil maturity in our whole blood assay.  In support of 
our hypothesis, we observed significantly decreased CD66b expression in the latent phase of 
infection and significant correlation between neutrophil expression and association with 
intraphagosomal reporter beads (Figure 3). In addition, we observed decreased monocyte - bead 
association in the latent and convalescent phases of infection using our whole blood phagocytosis 
assay. These results, coupled with previous evidence (33), suggest that density isolation of 
neutrophils limited our ability to measure the compensatory anti-inflammatory response using the 
opsonophagocytosis assay. An alternative neutrophil purification technique (e.g. magnetic negative 
cell selection) could mediate for this effect but requires further investigation.  
 
We used the M12-1 fragment of Streptococcal Group A emm12 protein, a relevant immunogenic 
peptide control that has been described as a virulence factor for Streptococcal Group A infection 
(34) and induces adaptive immunogenic responses in mice (35). We found no increase in neutrophil 
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bacterial killing using this control peptide so pragmatically used DEPC water as the vehicle control 
for the remainder of the study, as per previously published work (14,15). For the whole blood 
phagocytosis assay we noted convergence of results after 60 minutes incubation between P4 peptide 
and vehicle control stimulated samples. For oxidation ratio we highlight the plateau in oxidation 
ratio observed using this method. Vehicle control samples reached this plateau but at a slower rate 
than samples stimulated with P4 peptide. There was also a reduced but still significant difference in 
neutrophil-bead association at 60 minutes; this could be due to neutrophil saturation (only a 
proportion of neutrophils will associate with beads) or digestion of beads within the phagolysome 
but these hypotheses require further investigation. The purpose of this study was to measure cellular 
response to P4 peptide; as such we did measure additional inflammatory mediators. Previous work 
demonstrates that P4 peptide stimulation does not influence cellular release of a number of 
inflammatory cytokines (15). Future work should seek to determine the influence of inflammatory 
mediators on P4 peptide activity. 
 
There was a relatively high drop out for convalescent samples in our cohort. Mortality accounted 
for 18/36 of dropout but other patients were too unwell to attend or declined our invitation citing 
multiple other hospital appointments – this highlights the persistent morbidity often seen after 
critical illness. The purpose of the healthy volunteer cohort was to standardise study assays (healthy 
volunteer P4 peptide activity is previously published (15)). The small number of samples and 
differences in volunteer demographics (age, BMI and co-morbidities) limit our ability to directly 
compare patient and volunteer samples and draw conclusions about the presence and onset of 
compensatory anti-inflammatory response syndrome in our patient cohort. In addition, the 
demographic variation of our study group was limited (52/54 patients were white); this limits our 
ability to extrapolate our results to a more diverse cohort. Currently, this therapeutic strategy is 
subject to pre-clinical toxicology investigations in preparation for early phase clinical trials. This 
study will guide future clinical studies as we seek to further refine the target patient population. 
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Conclusion 
In conclusion, augmented passive immunotherapy using P4 peptide significantly increased 
phagocytic killing in samples taken from patients admitted to critical care with severe infection. The 
microbiological opsonophagocytic assay was supported by a flow cytometric whole blood assay 
that demonstrated increased intraphagosomal reporter bead association and oxidation in both 
neutrophils and monocytes. P4 peptide boosted the innate immune response to infection, enhancing 
bacterial killing by key immune effector cell populations and demonstrates clear potential as a 
future treatment for the most common causes of severe infection.  
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Table 1 
Parameter Early (n=54) Latent (n=39) Convalescent (n=18) 
SOFA score 8 (5-12) 2 (1-5) 0 (0-0) 
Mechanical ventilation 35 (64.8%) 18 (46.2%) 0 (0%) 
Cardiovascular support 36 (66.7%) 4 (10.3%) 0 (0%) 
Renal replacement 
therapy 
7 (13.0%) 3 (7.5%) 0 (0%) 
 
Table 1: Illness severity and required organ support in early, latent and convalescent phases 
of infection. Table demonstrates the change in sequential organ failure assessment score (median, 
IQR) in each phase of infection and the number (%) of patients who required mechanical 
ventilation, cardiovascular support (noradrenaline 31/36) and renal replacement therapy. 54/54 
early, 29/39 latent and 0/18 convalescent phase blood samples were taken with patients on critical 
care wards. 
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Table 2 
Group Independent variable Median IQR 
Organ support 
(days) 
Mechanical ventilation 6 0-10 
Cardiovascular support 7 0-15 
Length of stay 
(days) 
Critical care 9 5-16 
Hospital 20 11-40 
Mortality 
Critical care 14 (25.9%)  
Hospital 18 (34.0%)  
28 day 18 (34.0%)  
 
Table 2: Clinical outcome measures from critical care patient cohort (n=54). Table displays 
median and interquartile range values for organ support and length of stay variables. For mortality 
values table displays n (%). 
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Methods 
Trial design and participants 
We prospectively recruited patients with severe sepsis who required admission to critical care. 
Sepsis, severe sepsis and septic shock were defined according to American College of Chest 
Physician - Society of Critical Care Medicine (ACCP-SCCM) criteria [1]. Briefly, sepsis is an 
infection that causes systemic inflammatory response syndrome (SIRS), severe sepsis is sepsis with 
end organ dysfunction and septic shock is sepsis with acute circulatory failure. Patients were 
recruited from critical care units at two university teaching hospitals: Aintree University Hospital 
NHS Foundation Trust and the Royal Liverpool University Hospital between February 2014 and 
June 2015; the last sample was taken in September 2015. Patient inclusion criteria were: age >18, 
recruitment within 48 hours of diagnosis, presence of severe sepsis (defined as above) and 
respiratory, abdominal or urogenital source of infection (predominant causes in critical care [2]). 
Patient exclusion criteria were: specific immunocompromising condition or therapy (e.g. 
chemotherapy), pregnancy, deemed inappropriate by responsible clinician (e.g. life expectancy < 48 
hours), enrolment in an interventional study that might influence study results and failure to obtain 
consent. Blood samples were taken at day 0, 7 and after 3-6 months to measure neutrophil and 
monocyte activity in early, latent and convalescent phases of sepsis. Healthy volunteers were also 
recruited at the Clinical Research Facility, Royal Liverpool University Hospital and blood sampled 
at matched intervals. Inclusion criteria for healthy volunteers were: no current illness, age>18 and 
able to travel to the research facility. The North Wales NHS Research Ethics Committee approved 
this study on the 18th November 2013 (13/WA/0353). Written consent was obtained for all 
participants either directly or by a nominated consultee if incapacitated. Subsequently, written 
retrospective consent was obtained from patients that recovered. A CONSORT diagram details 
patient screening and inclusion for this study (Figure S1). 
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Clinical data 
We prospectively recorded patient demographic data, physiological variables, clinical laboratory 
results, microbiology data, organ support, outcome and markers of illness severity including Acute 
Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure 
Assessment (SOFA). Data collection was completed in September 2015. Pragmatic clinical 
outcome measures were selected a priori to determine if output from the laboratory assays could 
predict clinically relevant measures. These were: ventilator dependent days [3], cardiovascular 
support days, intensive care length of stay, ICU mortality and 28 day mortality. In addition, clinical 
factors were selected a priori to determine association with assay results. These were: age, gender, 
need for mechanical ventilation, cardiovascular support or renal replacement therapy, APACHE II 
score, SOFA score, Charlson Index, P/F ratio, lactate, white cell count, neutrophil count, platelet 
count, creatinine level, and bilirubin level. 
 
Laboratory 
Peptide synthesis: P4 peptide as described was synthesised with the sequence  
LFVESSVKRRPMKTVSQDTNIPIYAQIF. The peptide was synthesized and purified at the Centre 
for Disease Control facility, Atlanta, Georgia, USA. An Advanced ChemTech 396 multiple peptide 
synthesizer was used to synthesize P4 using standard and modified 9-fluorenyl-methoxycarbonyl 
(Fmoc) protocols [4–6] resulting in a free N- and C-terminus. P4 peptide batches were prepared at 
>97% purity (measured by high-pressure liquid chromatography, HPLC), transported on dry ice to 
the UK and then stored at -20oC until the day of use. For each sample peptide was solubilized in 
diethylpyrocarbonate (DEPC) water (1mg/ml OPKA and 4mg/ml whole blood assay) and stored at 
4oC until immediately before addition to assays. M12-1 is a peptide fragment of Streptococcal 
Group A emm12 protein (synthesised as above by Centres for Disease Control, US) and this was 
used as a peptide control. M12-1 peptide is a well described virulence factor in Streptococcal Group 
A infection [7] and induces immunogenic responses in mice but not augmented phagocytic 
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responses [8].  Diethylpyrocarbonate (DEPC) water was used as solvent for the experimental 
solutions: 1mg/ml P4 peptide, 1mg/ml M12-1 peptide or plain DEPC water. 
 
Opsonophagocytosis killing assay (OPKA) 
The primary outcome measure for this study was neutrophil bacterial killing determined by a 
standard opsonophagocytosis assay with minor modifications [9].  Neutrophils from patient samples 
were isolated and incubated with live pneumococci, opsonins and either immunostimulatory peptide 
P4 or controls as below: 
 
Bacterial culture: Capsulated serotype 2 (D39 strain) pneumococci were grown in Todd Hewitt 
broth supplemented with 0.5% yeast extract (THY) at 37oC 5% CO2 until optical density 0.3-0.4 
was reached, measured at 600nm. After the pause of the liquid culture, bacteria were centrifuged at 
13,000rpm for 15min, broth removed and bacteria pellet resuspended in THY 10% glycerol, 
aliquoted and stored at -80oC. Bacterial concentration (CFU/ml) was quantified and standardised 
using the Miles and Misra technique [10]. 
  
Neutrophil isolation: Briefly, heparinised whole blood was separated by density centrifugation 
(with Histopaque® 1077 and 1119 at room temperature) into serum, peripheral blood mononuclear 
cells, polymorphonuclear leukocytes (PMNL) and red blood cells. The PMNL layer was removed 
and red blood cell contaminants lysed (Biolegend, US) prior to enumeration on a haemocytometer. 
Viability was assessed using Trypan blue (<90% viability excluded). PMNLs were then diluted in 
opsonisation buffer (Hanks Balanced Salt Solution with calcium and magnesium mixed with 1% 
gelatin at a 9:1 ratio) to a concentration of 1.7 x 106 PMNL/ml immediately prior to use in the 
opsonophagocytosis assay. 
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Bacterial opsonisation: For each assay an aliquot of standardised solution frozen D39 (ST2) 
bacteria was thawed and serially diluted to a concentration of 5 x 104 CFU/ml. Human intravenous 
antibody (Gammunex, Grifols, Inc.) was used as the opsonin, diluted to a 1 in 4 concentration with 
Hanks Balanced Salt Solution with magnesium and calcium (HBSS+/+). An opsonised bacterial 
suspension was prepared by adding 500μL of diluted IVIG to 500μL of the bacterial suspension in a 
clear bijoux tube. A non-opsonised bacterial suspension was was prepared by adding 500μL 
HBSS+/+ to 500μL of the bacterial suspension in a clear bijoux tube.  Both bijoux tubes were then 
incubated at 37oC for 20 minutes on a shaking incubator (100 RPM). 
 
Opsonophagocytosis assay: Twenty microliters of the opsonised pneumococcal solution (500 
bacteria), 10μL of baby rabbit complement (Mast Group, Merseyside UK) and 20μL of the 
experimental solution (peptide P4, control peptide or DEPC water control) were added in triplicate 
to a 96 well plate. Finally, 30μl of the 1.7 x 106 PMNL/ml/well solution (51,000 PMNL) was added 
to the solution. The result was a final volume of 80μl with a multiplicity of infection (MOI) 100:1. 
Appropriate controls wells were used with non-opsonised bacteria, heat inactivated complement 
(incubated at 56oC for 30minutes), plain opsonisation buffer and plain DEPC water also added in 
triplicate to a 96 well plate. The 96 well plate was then covered and incubated at 37oC for 
45minutes with shaking (300 RPM). Subsequently, the plate was placed on ice for 15minutes to 
arrest the phagocytic process. After incubation, 10μL of the opsonophagocytic solution was taken 
from each well with a multiplex pipette and plated onto blood agar. 
 
Colony forming unit enumeration: Blood agar plates were incubated at 37oC with 5% CO2 for 18-
24 hours. The number of colonies forming units that grew from each 10μL were then counted the 
mean of the triplicate calculated. Neutrophil bacterial killing index was calculated as: 1 – 
(experimental well divided by non-PMN control well). The experimental well components were: 
isolated PMNLs, opsonised bacteria and complement with either P4 peptide, M12-1 peptide (12 
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samples) or vehicle control. The non-PMN control well components were: opsonised bacteria and 
complement. The effect of P4 was calculated as the absolute difference between the paired killing 
indices. 
 
Whole blood phagocytosis assay (WBPA) 
The whole blood phagocytosis assay was used to investigate how stimulation with P4 peptide 
influenced neutrophil association with intraphagosomal reporter beads and their subsequent 
oxidation within the phagosome. This assay builds upon previously published work using 
intraphagosomal reporter beads [11]. This assay was performed in parallel with the 
opsonophagocytosis assay from the same patient sample.  
 
Intraphagosomal reporter bead manufacture: Carboxymethylated silica beads (Kisker Biotech, 
Germany - 3μm diameter) were incubated for 20 minutes with a N,N’-dicyclohexylcarbodiimide 
solution (Sigma, US) and subsequently washed and pelleted. These carbodiimide linked beads were 
then added to a coupling solution (sodium borate 0.1M pH 8.0), defatted bovine serum albumin 
(Sigma, US) and human immunoglobulin (IgG, Sigma, US) and incubated for 16hours. Beads were 
then washed and pelleted. IgG labelled beads were then added to a solution of reporter 
fluorochrome (OxyBurst Green, FITC, Invitrogen) and dimethylsulfoxide (DMSO) and incubated 
for 1 hour. The beads were then washed and this step once. Subsequently the beads were coupled to 
the calibrator Alexa fluor 405 (Pacific Blue, Invitrogen) using the two-step process as above. The 
IgG and fluorophore labelled beads were then washed, suspended in 0.02% sodium azide solution 
and divided into 90μl aliquots. Subsequently, beads were stored in the dark at -20oC until use. 
 
Assay constituents: Materials for the bead assay were defrosted and prepared on the day of blood 
sampling. One aliquot per blood sample of intraphagosomal reporter beads was washed in 1ml of 
Roswell Park Memorial Institute (RPMI) media (Invitrogen, US) and pelleted using a 30s spin at 
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13.3xG. This process was repeated three times to remove the sodium azide. Subsequently, beads 
were resuspended in a solution of 1.8ml RPMI (30 x 106 beads /ml). Experimental solutions were 
prepared (P4 peptide 4mg/ml, DEPC water and LPS 100ng/ml). Lipopolysaccharide (LPS) was 
used as a positive control with pre-made aliquots defrosted on the day of use (100ng/ml stored at -
80oC). Subsequently, aliquots of beads were mixed with the experimental solutions (10:2 parts). 
The P4 and DEPC solutions were then subdivided into 120μl aliquots for each incubation time point 
(0, 10, 20, 30, 45 and 60 minutes). One LPS solution was made for 45 minutes incubation. Samples 
were stored in the dark at room temperature prior to addition of whole blood at specified time points 
- see below. 
 
Incubation and processing: After venepuncture, citrated blood (4.5ml 9NC (BD)) was placed on 
an automated mixer to prevent settling and permitted to reach room temperature. Subsequently, 
100µl of whole blood was added to the paired bead solutions at pre-defined time intervals (60, 45, 
30, 20, 10 and 0 minutes), commencing with the 60-minute sample. Blood and bead solutions were 
mixed with the pipette and then placed in a rotating incubator (300RPM) in the dark at 37oC. The 
blood tube was placed on the mixer between time intervals. After 60 minutes all tubes were placed 
on ice in the dark for 10 minutes to arrest biological activity (0 minute tubes placed directly on ice). 
Subsequently, 2ml of red cell lysis buffer (5ml 10X RBC lysis buffer, Biolegend, US diluted in 
45ml distilled water at 4oC) was added to each tube and the experimental solution resuspended. The 
tubes were then placed at 4oC for 20 minutes to permit red cell lysis. Following the lysis step, the 
tubes were centrifuged at 1300rpm for 5 minutes with brake. The supernatant was then poured away 
to leave the cell pellet. The pellet was then resuspended and washed in 2ml Dulbecco's phosphate-
buffered saline (DPBS-/-), no calcium and no magnesium. The centrifugation step was then repeated 
and supernatant poured away to leave a straw coloured pellet. The pellet was then resuspended in 
300µL DPBS-/- and stored on ice, in the dark, until flow cytometric acquisition (within 2 hours). 
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Fluorescence Minus One (FMO) controls: RPMI was substituted for intraphagosomal reporter 
beads to exclude cellular autofluorescence after 0 and 45 minutes incubation with P4 peptide and 
vehicle control solutions. RPMI was substituted for blood and plain silica beads added to bead 
controls. Beads were incubated for 45 minutes to exclude independent intraphagosomal bead 
degradation/oxidation with P4 peptide and vehicle control solutions. These biological comparison 
controls were used to set negative and positive boundaries for flow cytometric analysis. 
 
Cell surface markers: Cellular expression of CD14 (monocyte marker) and CD66B (neutrophil 
marker) were measured in a subset of samples. CD66b antibody was used to measure neutrophil 
cell surface expression of carcinoembryonic antigen gene family member 6 (CGM6). To do this, we 
evaluated an additional paired (vehicle control vs. P4 peptide) assay at 45 minutes with cell surface 
markers applied prior to acquisition. Samples that identified less than 750 monocytes were excluded 
from the analysis. The antibodies used were: PerCP-Cy 5.5 anti-human CD14 (clone MΦP9, mouse 
IgG2b, BD Pharmingen) and APC anti-human CD66b (clone G10F5, mouse IgMκ, Stemcell 
technologies).  
 
Flow cytometric acquisition and analysis: Compensation beads (BD Biosciences) were used to 
create compensation matrices and a sequential cell gating strategy used to identify populations of 
interest. All samples were acquired using a BD LSRII Flow Cytometer equipped with three lasers 
emitting at 405, 488 and 633nm (Becton Dickinson) using FacsDiva (software version 6.1, BD 
Biosciences) and FlowJo (software version 10.7, Tree Star) flow cytometry software. At least 
50,000 events were acquired per sample within a gate targeting the neutrophil population 
(according to FSC-A and SSC-A parameters).  
 
For the whole blood phagocytosis assay the gating strategies are outlined in Figure S2. Neutrophil 
and intraphagosomal reporter bead association was determined as the percentage of gated (FSC-A, 
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SSC-A) neutrophils that expressed intraphagosomal reporter bead calibrator fluor. Monocyte and 
intraphagosomal reporter bead association was determined as the percentage of gated (CD14 
positive) monocytes that expressed calibrator fluorochrome. Intraphagosomal reporter bead 
oxidation was calculated as a ratio of reporter fluorochrome mean fluorescence intensity (MFI, 
FITC) divided by calibrator fluorochrome MFI (Pacific Blue) in neutrophils and monocytes 
associated with beads. 
 
Statistical analysis 
Power calculations for this study were based on preliminary work that examined P4 peptide in 
patients with severe community acquired pneumonia (unpublished). The primary outcome was 
neutrophil mediated bacterial killing (%). P4 enhanced neutrophil bacterial killing from a mean 
(SD) of 30.78 (23.28) to a mean (SD) of 46.80 (12.79). Using these data we determined that 
recruitment of 58 patients would provide 90% power (alpha level <0.05, two tailed) to detect a 16% 
increase in bacterial killing. 
 
Data were summarized using median (IQR), examined for normality and appropriate statistical tests 
applied. Linear mixed-model regression analyses were applied to the data to adjust for repeated 
measures in individual patients and determine if phase or source of infection were independent 
predictors of response to P4 peptide stimulation. In addition, for early phase samples, area under the 
curve was calculated using a statistical pharmacokinetic function (pksumm) to summarize output 
from the whole blood phagocytosis assay (all time points: 0, 10, 20, 30, 45 and 60 minutes) to 
determine association with clinical parameters (Figure S5). Linear and logistic regression analyses 
were performed to examine association between potential clinical predictors of assay output and to 
examine if the assay predicted clinical outcome measures. The effect of P4 was calculated as the 
absolute difference between the curves. Statistical analysis was performed using STATA 13.1, 
Statacorp, 2013. 
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Results 
P4 peptide concentration in whole blood phagocytosis assay 
The starting point for P4 peptide concentration was that used for the opsonophagocytosis assay. For 
this assay, 20μl 1mg/ml P4 peptide in DEPC water was added to the bacterial, neutrophil and 
complement solutions to constitute a total volume of 80μl per well (250μg/ml P4 peptide in 
solution). Therefore, using the equation V1 x C1 = V2 x C2, 20μl of 2.75mg/ml P4 peptide in DEPC 
was added to the blood-bead solution to (total volume of 220μl). However, in validation 
experiments, no difference between vehicle control and P4 peptide stimulated samples was 
observed at this concentration. Therefore, a titrated concentration experiment was used to determine 
optimal dose for this assay (Table S1). For this experiment, blood from a healthy volunteer was 
separated into aliquots and incubated with intraphagosomal reporter beads for 30 minutes with 
increasing doses of P4 peptide. Based on this work 4mg/ml P4 peptide in 20μl DEPC (final 
concentration 364μg/ml) was used for the finalised assay. 
P4 peptide 
concentration 
Neutrophil-bead association Bead oxidation ratio 
0 mg/ml 8.4% 1.12 
2.75 mg/ml 8.6% 1.18 
4 mg/ml 17.5% 1.38 
5 mg/ml 14.3% 1.30 
10 mg/ml 9.1% 1.36 
 
Table S1: Illustrates results from a P4 peptide titration experiment to determine optimal dose for 
the whole blood phagocytosis assay. Citrated blood samples 100μl were incubated with 
intraphagosomal reporter beads (30 x 106 beads/ml in RPMI, 100μl) and 20μl of experimental 
solution (concentration as above) for 30 minutes. Samples were then lysed, processed and acquired 
by flow cytometry. Neutrophils were gated according to FSC-A and SSC-A parameters. Neutrophil-
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bead association was defined as the proportion of neutrophils that expressed intraphagosomal 
reporter bead calibrator fluor (Pacific blue). Intraphagosomal reporter bead oxidation ratio was 
defined as mean fluorescence intensity reporter fluor (FITC) divided by calibrator fluor (Pacific 
Blue). 
 
 
Association between blood parameters and baseline neutrophil bacterial killing 
 
Group Independent variable Coef. Std.Err. p-
value 
R2 
Blood 
parameters 
White Cell Count -0.14 0.17 0.402  
Neutrophils -0.15 0.18 0.411  
Platelets -0.002 0.01 0.854  
Creatinine -0.02 0.01 0.116  
Bilirubin -0.005 0.03 0.844  
 
Table S1: Univariate regression analyses to determine association between patient clinical 
factors and baseline neutrophil bacterial killing. Table demonstrates the relationship between 
clinical factors (independent variables) and neutrophil bacterial killing calculated as (1 – (colony 
forming units experimental well) / (colony forming units opsonised non-neutrophil control well)) x 
100. Coef. = coefficient. Std.Err. = standard error. Linear regression analysis. 
 
Association between blood parameters and P4 peptide activity in the opsonophagocytosis 
killing assay 
 
Group Independent variable Coef. Std.Err. p-
value 
R2 
Blood 
parameters 
White Cell Count 0.13 0.1 0.233  
Neutrophils 0.14 0.12 0.258  
Platelets -0.002 0.007 0.790  
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Creatinine 0.02 0.008 0.004 0.151 
Bilirubin 0.009 0.02 0.591  
 
Table S2: Univariate regression analyses to determine association between patient clinical 
factors and response to P4 peptide in neutrophil bacterial killing. Table demonstrates the 
relationship between clinical factors (independent variables) and absolute difference in bacterial 
killing calculated between neutrophils exposed to P4 peptide and vehicle control. Killing index is 
calculated as: (1 – (colony forming units experimental well) / (colony forming units opsonised non-
neutrophil control well)) x 100. Coef. = coefficient. Std.Err. = standard error. Linear regression 
analysis. 
 
Opsonophagocytosis assay analysis 
 
Raw, non-adjusted, data from the opsonophagocytosis killing assay is presented. This data was used 
to generate the mixed-model regression analysis to adjust for the hierarchical nature of sampling 
(one patient sampled three times). 
 
Opsonophagocytosis assay: raw data 
 
 
 
 
 
 
 
Sample n Contro
l 
C.I. P4 C.I. 
Early  54 15.26 12.56 – 17.96 24.44 21.78 – 27.09 
Latent 39 21.08 18.14 – 24.03 28.72 25.21 – 32.23 
Convalescent 18 23.87 17.44 – 30.30 32.99 26.16 – 39.81 
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The neutrophil bacterial killing index is significantly higher in patient samples stimulated 
with P4 peptide in the early, latent and convalescent phases of severe infection. Table 
demonstrates mean and 95% confidence intervals (C.I.) for neutrophil bacterial killing index in 
samples stimulated with control (DEPC water) compared to P4 peptide (250μg/ml). This raw data 
was used for the mixed model regression analysis described in Figure 1 of the main manuscript. 
Statistical analysis by paired t-test. 
 
The table below demonstrates the output from the mixed model regression analysis for patient 
opsonophagocytosis assay outcomes. Coefficients from this analysis were used in linear comparison 
analyses to generate point estimates and 95% confidence intervals used to generate Figure 1 in the 
main manuscript. 
 
Opsonophagocytosis assay: adjusted data 
Variable Coefficient P value C.I. 
Latent phase (vs. early)  4.88 <0.001 2.39 – 7.36 
Convalescent phase (vs. early) 7.13 <0.001 3.23 – 11.04 
P4 peptide (vs. control) 8.55 <0.001 6.35 – 10.76 
Constant 15.54 <0.001 12.98 – 18.09 
 
Random-effects 
parameters 
Estimate Std. Err. C.I. 
Individual variance 6.34 0.92 4.77 – 8.43 
Residual variance 8.13 0.44 7.28 – 9.10 
 
Mixed-model regression analysis for the opsonophagocytosis assay. Table illustrates significant 
factors that influence neutrophil bacterial killing in the opsonophagocytosis killing assay. Bacterial 
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killing index is calculated as: (1 – (colony forming units experimental well) / (colony forming units 
opsonised non-neutrophil control well)) x 100). The constant value represents the bacterial killing 
index by neutrophils from patients admitted to critical care with respiratory infection in the early 
phase of infection when exposed to vehicle control. Number of observations = 210, number of 
groups = 54, average observations per group = 3.9 (min 2, max 6). Individual variance refers to 
random effects at the patient level (level two error). Residual variance refers to level one error 
variance (variance of the overall error term). The coefficient describes the mean difference between 
groups. C.I. = confidence interval, Std. Err. = standard error. 
 
Whole blood phagocytosis assay: neutrophil-bead association analysis 
 
Raw, non-adjusted, data from the whole blood phagocytosis assay neutrophil-bead association 
output is presented below. This data was used to generate the mixed-model regression analysis to 
adjust for the hierarchical nature of sampling (one patient sampled three times).  
 
The following table details the mixed-model regression analysis for neutrophil-bead association, 
including the interaction between P4 peptide and incubation period. . Coefficients from this analysis 
were used in linear comparison analyses to generate point estimates and 95% confidence intervals 
used to generate Figure 2A in the main manuscript. 
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Whole blood phagocytosis assay neutrophil-bead association: raw data 
 
Sample n Incubatio
n 
Contro
l 
C.I. P4 C.I. 
Early 44 
0 1.60 0.27 – 2.94 1.31 0.14 – 0.53 
10 7.87 5.64 – 10.10 11.68 8.37 – 14.99 
20 14.24 10.49 – 
17.99 
23.49 18.84 – 28.14 
30 17.70 13.16 – 
22.25 
32.07 26.07 – 38.08 
45 22.38 17.55 – 
27.21 
37.01 31.15 – 42.87 
60 34.65 28.79 – 
40.52 
43.51 37.30 – 49.71 
Latent 32 
0 0.60 0.39 – 0.81 0.41 0.29 – 0.53 
10 4.11 2.56 – 5.67 7.35 4.34 – 10.36 
20 7.04 4.69 – 9.40 14.44 10.49 – 18.39 
30 9.78 6.88 – 12.68 19.89 15.25 – 24.53 
45 15.09 11.36 – 
18.82 
27.79 22.16 – 33.42 
60 29.86 23.69 – 
36.02 
33.80 27.24 – 40.35 
Convalescent 18 
0 0.72 0.28 - 1.16 0.40 0.15 – 0.65 
10 2.00 0.40 – 3.62 5.98 1.66 – 10.31 
20 3.21 0.81 – 5.61 10.84 3.29 – 18.38 
30 6.50 2.12 – 10.87 16.80 7.70 – 25.89 
45 11.26 5.24 – 17.28 23.39 13.13 – 33.66 
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Intraphagosomal reporter bead association with neutrophils is significantly higher in whole 
blood stimulated with P4 peptide from patients admitted to critical care with severe sepsis. 
Table demonstrates intraphagosomal reporter bead association with neutrophils after incubation for 
0, 10, 20, 30, 45 and 60 minutes with P4 peptide (364μg/ml) and vehicle control (DEPC water) in 
three phases of infection (Early = day 0, Latent = day 7 and Convalescent = 3-6 months later). 
Neutrophils were selected gated on flow cytometry by forward and side scatter. Association with 
intraphagosomal reporter beads was determined by concomitant expression of the calibrator flour 
(pacific blue) of the intraphagosomal reporter beads. This raw data was used for the mixed model 
regression analysis described in Figure 2 of the main manuscript. Mean and 95% confidence 
intervals, statistical analysis by paired t-test. 
Whole blood phagocytosis assay neutrophil-bead association: adjusted data 
Variable Coef. Std. Err. P value 95% C.I. 
Latent phase (vs. early) -7.58 0.81 <0.001 -9.17 – -5.99 
Convalescent phase (vs. early) -9.69 1.05 <0.001 -11.75 – -
7.63 
Incubation 10min (vs. 0 min) 4.38 1.58 0.006 1.28 – 7.47 
Incubation 20min (vs. 0 min) 8.58 1.58 <0.001 5.49 – 11.68 
Incubation 30min (vs. 0 min) 11.65 1.58 <0.001 8.56 – 14.74 
Incubation 45min (vs. 0 min) 16.67 1.58 <0.001 13.58 – 19.77 
Incubation 60min (vs. 0 min) 29.11 1.58 <0.001 26.02 – 32.20 
xP4 (vs. control) at 0 min -0.26 1.58 0.868 -3.35 – 2.83 
Incubation 10min xP4 (vs. control) 3.91 2.23 0.080 -0.46 – 8.28 
Incubation 20min xP4 (vs. control) 8.57 2.23 <0.001 4.20 – 12.94 
60 19.94 10.49 – 
29.40 
30.85 17.92 – 43.78 
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Incubation 30min xP4 (vs. control) 12.38 2.23 <0.001 8.00 – 16.76 
Incubation 45min xP4 (vs. control) 13.76 2.23 <0.001 9.39 – 18.13 
Incubation 60min xP4 (vs. control) 7.84 2.23 <0.001 3.46 – 12.21 
Constant 5.33 1.68 0.001 2.05 – 8.62 
 
Random-effects 
parameters 
Estimate Std. Err. C.I. 
Individual variance 8.52 0.93 6.89 – 10.55 
Residual variance 10.81 0.23 10.37 – 11.28 
 
Mixed model regression analysis to demonstrate factors and interactions that influence 
intraphagosomal reporter bead association with neutrophils. The dependent outcome variable is 
intraphagosomal reporter bead association with neutrophils calculated as the proportion of 
neutrophils identified by flow cytometry that fluoresce with pacific blue (calibrator fluor of 
intraphagosomal reporter beads). The constant value represents the proportion of neutrophils 
associated with a bead(s) in study participants at incubation time 0 minutes when exposed to vehicle 
control (DEPC water). When whole blood and intraphagosomal beads were stimulated with P4 
peptide (364μg/ml) there was significant interaction with the length of incubation (Incubation xP4). 
The proportion of neutrophils associated with an intraphagosomal reporter bead(s) was significantly 
increased in the presence of P4 peptide at 20, 30, 45 and 60-minute incubations but not at 0 or 10 
minutes. This data was used in linear comparison analysis to construct data for Figure 2, main 
manuscript. Number of observations: 1127 (groups: 51). Coef = coefficient, C.I. = 95% confidence 
interval, Std. Err. = standard error. 
 
Whole blood phagocytosis assay: neutrophil intraphagosomal reporter bead oxidation 
analysis 
 
Raw, non-adjusted, data from the whole blood phagocytosis assay reporter bead oxidation output is 
presented below. This data was used to generate the mixed-model regression analysis to adjust for 
the hierarchical nature of sampling (one patient sampled three times).  
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The following table details the mixed-model regression analysis for intraphagosomal reporter bead 
oxidation, including the interaction between P4 peptide and incubation period. Coefficients from 
this analysis were used in linear comparison analyses to generate point estimates and 95% 
confidence intervals used to generate Figure 2B in the main manuscript. 
 
Whole blood phagocytosis assay neutrophil intraphagosomal bead oxidation: raw data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample n Incubatio
n 
Contro
l 
C.I. P4 C.I. 
Early 44 
0 0.92 0.79 – 1.05 0.87 0.75 - 1.00 
10 1.55 1.39 – 1.72 1.86 1.65 – 2.07 
20 1.72 1.51 – 1.92 2.10 1.85 – 2.35 
30 1.76 1.56 – 1.96 2.11 1.84 – 2.39 
45 1.81 1.57 – 2.06 2.10 1.83 – 2.37 
60 1.88 1.62 – 2.15 1.93 1.68 – 2.18 
Latent 32 
0 0.84 0.72 – 0.96 0.89 0.77 – 1.02 
10 1.33 1.17 – 1.49 1.74 1.45 – 2.03 
20 1.52 1.30 – 1.73 1.99 1.52 – 2.45 
30 1.55 1.40 – 1.70 1.91 1.70 – 2.12 
45 1.70 1.46 – 1.94 1.93 1.68 – 2.17 
60 1.84 1.56 – 2.13 1.92 1.65 – 2.19 
Convalescent 18 
0 0.66 0.53 – 0.79 0.78 0.62 – 0.94 
10 1.10 0.88 – 1.32 1.41 1.17 - 1.66 
20 1.28 0.98 – 1.59 1.76 1.27 – 2.26 
30 1.30 1.05 – 1.54 1.71 1.36 – 2.06 
45 1.40 1.13 – 1.68 1.96 1.51 – 2.41 
60 1.64 1.26 – 2.04 1.94 1.44 – 2.47 
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Intraphagosomal reporter bead oxidation ratio is significantly higher in whole blood 
stimulated with P4 peptide from patients admitted to critical care with severe sepsis. Table 
demonstrates the oxidation ratio of intraphagosomal reporter beads associated with neutrophils after 
incubation for 0, 10, 20, 30, 45 and 60 minutes with P4 peptide (364μg/ml) and vehicle control 
(DEPC water) in three phases of infection (Early = day 0, Latent = day 7 and Convalescent = 3-6 
months later). Oxidation ratio is calculated: median fluorescence intensity FITC (reporter fluor) 
divided median fluorescence intensity pacific blue (calibrator fluor). This raw data was used for the 
mixed model regression analysis described in Figure 2 of the main manuscript. Mean and 95% 
confidence intervals, statistical analysis by paired t-test. 
 
Whole blood phagocytosis assay neutrophil intraphagosomal bead oxidation: adjusted data 
Variable Coef. Std. Err. P value 95% C.I. 
Latent phase (vs. early) -0.26 0.04 <0.001 -0.34 – -0.19 
Convalescent phase (vs. early) -0.30 0.05 <0.001 -0.40 – -0.20 
Incubation 10min (vs. 0 min) 0.55 0.08 <0.001 0.40 – 0.69 
Incubation 20min (vs. 0 min) 0.72 0.08 <0.001 0.57 – 0.87 
Incubation 30min (vs. 0 min) 0.76 0.08 <0.001 0.61 – 0.91 
Incubation 45min (vs. 0 min) 0.86 0.08 <0.001 0.71 – 1.00 
Incubation 60min (vs. 0 min) 0.98 0.08 <0.001 0.83 – 1.13 
xP4 (vs. control) at 0 min 0.02 0.08 0.802 -0.13 – 0.17 
Incubation 10min xP4 (vs. 
control) 
0.32 0.11 0.003 0.11 – 0.53 
Incubation 20min xP4 (vs. 
control) 
0.42 0.11 <0.001 0.21 – 0.62 
Incubation 30min xP4 (vs. 
control) 
0.35 0.11 0.001 0.14 – 0.56 
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Incubation 45min xP4 (vs. 
control) 
0.30 0.11 0.005 0.09 – 0.51 
Incubation 60min xP4 (vs. 
control) 
0.09 0.11 0.416 -0.13 – 0.30 
Constant 0.98 0.09 <0.001 0.81 – 1.15 
 
Random-effects 
parameters 
Estimate Std. Err. C.I. 
Individual variance 0.48 0.05 0.39 – 0.59 
Residual variance 0.52 0.01 0.50 – 0.54 
 
Mixed model regression analysis to determine which factors influence intraphagosomal 
reporter bead oxidation ratio. The dependent outcome variable is intraphagosomal reporter bead 
oxidation ratio in gated (FSC, SSC) neutrophils) calculated as the median fluorescence intensity 
(MFI) of FITC (reporter fluor) divided by MFI Pacific blue (calibrator fluor). The constant value 
represents the oxidation ratio of intraphagosomal reporter beads in study participants at incubation 
time 0 minutes when exposed to vehicle control (DEPC water). When whole blood and 
intraphagosomal beads were stimulated with P4 peptide (364μg/ml) there was significant 
interaction with the length of incubation (Incubation xP4). Oxidation of intraphagosomal reporter 
beads was significantly increased when stimulated with P4 peptide at 10, 20, 30 and 45 minute 
incubations but not at 0 and 60 minutes This data was used in linear comparison analysis to 
construct data for Figure 2, main manuscript. Number of observations: 1127 (groups: 51). Coef = 
coefficient, C.I. = 95% confidence interval, Std. Err. = standard error. 
 
Whole blood phagocytosis assay: monocyte-bead association analysis 
 
Raw, non-adjusted, data from the whole blood phagocytosis assay monocyte-bead association 
output is presented below. This data was used to generate the mixed-model regression analysis to 
adjust for the hierarchical nature of sampling (one patient sampled three times).  
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The following table details the mixed-model regression analysis for monocyte-bead association. . 
Coefficients from this analysis were used in linear comparison analyses to generate point estimates 
and 95% confidence intervals used to generate the following figure. 
 
Whole blood phagocytosis assay monocyte-bead association: raw data (A) 
 
 
 
Whole blood phagocytosis assay monocyte-bead association: adjusted data (B) 
Variable Coef. Std. Err. Z P value C.I. 
Latent phase (vs. early) -0.03 0.03 -0.96 0.337 -0.09 – 0.032 
Convalescent phase (vs. 
early) 
-0.15 0.05 -3.25 0.001 -0.24 – -0.06 
P4 peptide (vs. control) 0.08 0.03 3.30 0.001 0.03 – 0.13 
Constant 0.67 0.03 23.20 <0.001 0.61 – 0.72 
 
Random-effects 
parameters 
Estimate Std. Err. C.I. 
Individual variance 0.09 0.02 0.06 – 0.15 
Residual variance 0.12 0.01 0.10 – 0.14 
 
Sample n Contro
l 
IQR P4 IQR P value 
Early  21 0.73 0.65 – 0.78 0.80 0.71 – 0.83 0.003 
Latent 17 0.68 0.54 – 0.77 0.71 0.63 – 0.80 0.007 
Convalescent 6 0.53 0.47 – 0.64 0.65 0.59 – 0.77 0.028 
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Monocyte association with intraphagosomal reporter beads. A: Table demonstrates median and 
interquartile range for the percentage of monocytes (identified via side scatter and CD14 expression 
by flow cytometry) that were associated with intraphagosomal reporter beads. Statistical analysis by 
Wilcoxon rank-sum test. B: Table demonstrates the mixed model regression analysis to identify 
independent predictors of monocyte-bead association (defined as above) adjusting for repeated 
measures from individual patients. The constant value represents the proportion of monocytes 
associated with intraphagosomal reporter beads when incubated with vehicle control for 45 minutes 
in early phase samples. When whole blood and intraphagosomal beads were stimulated with P4 
peptide (364μg/ml) there was significant increase in association. There was a significant decrease in 
baseline (vehicle control) association in convalescent but not latent samples. Number of 
observations: 88 (groups: 31). Coef = coefficient, C.I. = 95% confidence interval, Std. Err. = 
standard error. 
 
 
 
P4 peptide stimulates significantly increased monocyte association with intraphagosomal 
reporter beads in samples from patients admitted to critical care with severe infection. Figure 
displays the mixed-model adjusted proportion (point estimate and 95% confidence interval) of 
monocytes associated with an intraphagosomal reporter bead after 45 minutes incubation with 
whole blood. Monocytes were identified by flow cytometry (side scatter and CD14 expression) and 
association with bead was determined by co-expression of gated monocyte with bead calibrator 
Copyright © 2016 by the Shock Society. Unauthorized reproduction of this article is prohibited.
fluor. The addition of P4 peptide increased the mean difference in monocyte-bead association 
compared to vehicle (DEPC water) control in early (75.2% vs. 67.0%, p<0.001), latent (72.2% vs. 
63.9%, p<0.001) and convalescent (60.0% vs. 51.7%, p<0.001) phases of infection. 
 
 
Whole blood phagocytosis assay monocyte intraphagosomal reporter bead oxidation 
 
Raw, non-adjusted, data from the whole blood phagocytosis assay monocyte intraphagosomal 
reporter bead oxidation is presented below. This data was used to generate the mixed-model 
regression analysis to adjust for the hierarchical nature of sampling (one patient sampled three 
times).  
 
The following table details the mixed-model regression analysis for monocyte intraphagosomal 
reporter bead oxidation. In this analysis, P4 peptide stimulation was significantly associated with 
monocyte reporter bead oxidation but phase was not such that a figure has not been constructed 
with this data. 
 
Whole blood phagocytosis assay monocyte intraphagosomal reporter bead oxidation: raw 
data (A) 
 
 
 
 
 
 
 
Sample n Contro
l 
IQR P4 IQR P value 
Early  21 0.91 0.67 – 1.35 1.08 0.96 – 1.69 <0.001 
Latent 17 1.14 1.00 – 1.40 1.58 1.10 – 1.83 <0.001 
Convalescen
t 
6 1.00 0.82 – 1.05 1.32 1.08 – 1.62 0.028 
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Whole blood phagocytosis assay monocyte intraphagosomal reporter bead oxidation: 
adjusted data (B) 
Variable Coef. Std. Err. Z P value C.I. 
P4 peptide 0.34 0.05 6.36 <0.001 0.23 – 0.44 
Constant 1.05 0.08 14.02 <0.001 0.91 – 1.20 
 
Random-effects 
parameters 
Estimate Std. Err. C.I. 
Individual variance 0.36 0.05 0.27 – 0.48 
Residual variance 0.25 0.02 0.21 - 0.30 
 
Oxidation ratio of intraphagosomal reporter beads associated with monocytes: A: Table 
demonstrates median and interquartile range for the oxidation ratio of intraphagosomal reporter 
beads that are associated with gated (SSC/CD14) monocytes (data not normally distributed). 
Oxidation ratio calculated as the median fluorescence intensity (MFI) of FITC (reporter fluor) 
divided by MFI Pacific blue (calibrator fluor). Statistical analysis by Wilcoxon rank-sum test. B: 
Table demonstrates the mixed model regression analysis to identify independent predictors of 
oxidation ratio of beads associated with monocytes (defined as above) adjusting for repeated 
measures from individual patients. The constant value represents the oxidation ratio when 
monocytes and beads were incubated with vehicle control for 45 minutes. When whole blood and 
intraphagosomal beads were stimulated with P4 peptide (364μg/ml) there was significant increase 
in oxidation. Phase of sepsis was not an independent predictor of oxidation in this analysis. Number 
of observations: 88 (groups: 31). Coef = coefficient, C.I. = 95% confidence interval, Std. Err. = 
standard error. 
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Whole blood phagocytosis assay positive control 
 
Paired LPS positive control samples (n=105) at 45 minutes incubation demonstrated significantly 
increased bead association (median 27.1% vs. 13.3%, p<0.001) and oxidation ratio (median 1.57 vs. 
1.41, p<0.001) compared to vehicle control samples but no significant difference in association 
(median 27.1% vs. 26.2%, p=0.313) and a significantly decreased oxidation ratio (median 1.57 vs. 
1.73, p=0.001) compared to P4 peptide stimulated samples, Wilcoxon signed rank tests. 
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Figure S2:
 
 
 
 
A 
 Flow cytometry gating strategies for the whole blood phagocytosis assay 
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Figure S2: Flow cytometry gating strategies for the whole blood phagocytosis assay. A: Figure 
demonstrates the neutrophil gating strategy: forward (FSC-A) and side scatter (SSC-A) were used 
to identify and acquire 50,000 neutrophils per sample. Singlets were then identified and within this 
gate the expression of Intraphagosomal reporter bead Pacific Blue (calibrator fluor) and FITC 
(reporter fluor) were measured. B: Figure demonstrates the monocyte gating strategy. 
Intraphagosomal reporter beads were found to bleed into the FSC-A/SSC-A gate for monocytes so 
we used cell surface CD14 expression and SSC-A to identify the monocyte subpopulation. Singlets 
were then identified and within this gate expression of intraphagosomal bead reporter fluor and 
calibrator fluor were measured as above. C: Figure demonstrates neutrophil maturity gating 
strategy: FSC and SSC were used to identify and acquire 50,000 neutrophils per sample and singlets 
were identified as above. Cell surface CD66B was used as a neutrophil maturity marker (APC) with 
intraphagosomal reporter bead calibrator and reporter fluor subsequently measured within this 
population.  
B 
C 
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Figure S3: M peptide, an alternative control for P4 did not increase neutrophil bacterial 
killing 
  
Figure S3: Control solutions for P4 peptide. Figure displays mean killing index and 95% 
confidence intervals for P4 peptide, M peptide and Vehicle (DEPC water) control (n=12). Mean 
bacterial killing was significantly higher for P4 peptide (22.77 C.I. 17.2-28.3) compared to M 
peptide (16.65 C.I. 11.4-21.9, p=0.003) and vehicle control (14.78 C.I. 9.1-20.5, p=0.001). There 
was no significant difference between M peptide and vehicle controls (p=0.366). Bacterial killing 
index was calculated as the proportion of colony forming units killed by neutrophils: (1 – (CFU 
count experimental well / CFU count non-neutrophil control well). The data were normally 
distributed (Shapiro-Wilk) and analysis performed by paired t-test. 
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Figure S4: Whole blood phagocytosis assay raw healthy volunteer data. 
 
 
Figure S4: Healthy volunteer samples and the influence of P4 peptide. A: Figure demonstrates 
non-adjusted data for healthy volunteer neutrophil association with intraphagosomal reporter beads 
at 0, 10, 20, 30, 45 and 60 minutes in sample 1 (n=8), sample 2 (n=9) and sample 3 (n=11) with P4 
peptide and vehicle control. B: Figure demonstrates non-adjusted data for healthy volunteer 
neutrophil oxidation of intraphagosomal reporter beads at 0, 10, 20, 30, 45 and 60 minutes in 
sample 1 (n=8), sample 2 (n=9) and sample 3 (n=11) with P4 peptide and control. Displayed are 
mean values and confidence intervals. Eleven volunteers were recruited in total for the study – 
laboratory capacity limited ability to process all blood samples at time points 1 and 2. 
 
A 
B 
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Figure S5: An illustration of area under the curve calculation for the whole blood 
phagocytosis assay, used to test association between potential clinical predictors and patient 
outcomes 
 
 
 
Figure S5: Whole blood phagocytosis area under the curve calculation illustration. A: Figure 
illustrates how the proportion of neutrophils (%) associated with intraphagosomal bead(s) changes 
according the length of incubation. An area under the curve (AUC) was calculated for the vehicle 
control samples (light grey shaded area) and for the absolute response to P4 peptide (dark grey 
shaded area): AUC P4 peptide response minus AUC vehicle control. B: Figure illustrates how the 
oxidation ratio of intraphagosomal repoter beads associated with neutrophils changes according the 
length of incubation. An AUC was calculated for the vehicle control samples (light grey shaded 
area) and for the absolute response to P4 peptide (dark grey shaded area): AUC P4 peptide response 
minus AUC vehicle control. 
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